Gene · 1613
NIH grants1,435
NIH grants whose papers are about the gene, through NIH's grant-paper links.
101 to 120 of 1,435
Download this page as JSON| Grant | Title | DAPK3 papers | Newest fiscal year |
|---|---|---|---|
| R01AI073843 | Pathobiology of heme inducible transporters in Gram positive pathogens | 1 | 2025 |
| R01AI093504 | Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning | 1 | 2025 |
| R01AI118807 | Central metabolism of Salmonella in the inflamed gut | 1 | 2025 |
| R01AI169386 | Mechanisms of visual transduction and light-driven behaviors in Aedes aegypti | 1 | 2025 |
| R01AR043369 | MITF from control of pigmentation to melanoma risk | 1 | 2025 |
| R01AR072304 | Therapeutic strategies for treatment of giant congenital melanocytic nevi | 1 | 2025 |
| R01AR077578 | Mechanisms of Cu-binding factors to promote myogenic gene expression | 1 | 2025 |
| R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 1 | 2025 |
| R01CA098371 | In Vivo Oncogene-Induced Tumorigenesis and Escape | 1 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 1 | 2025 |
| R01CA252224 | Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure | 1 | 2025 |
| R01CA262790 | The Role of Immature Tumor Subpopulations In Pediatric Rhabdomyosarcoma | 1 | 2025 |
| R01CA266298 | Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia | 1 | 2025 |
| R01CA266600 | EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA | 1 | 2025 |
| R01CA292507 | Molecular mechanisms of developmental reprogramming in colorectal cancer | 1 | 2025 |
| R01DK068271 | Therapeutic targeting of protein interactions to reverse MLCK1-mediated intestinal barrier loss and ameliorate disease. | 1 | 2025 |
| R01DK075787 | Biological Insights from Genetic Investigation of ANthropometric Traits (GIANT) Across the Allelic Spectrum | 1 | 2025 |
| R01DK125647 | Mechanistic insights into the crosstalk between iron metabolism and diabetes | 1 | 2025 |
| R01ES007331 | Mechanisms of Methylmercury Induced Neuronal Toxicity | 1 | 2025 |
| R01ES010563 | Mechanisms of Manganese Neurotoxicity | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1613/grants?page=6